Yaoshibang, a Guangzhou-based business-to-business (B2B) pharmaceutical trading platform, announced that it has completed a US$133 million new round of financing from Tiger Global Management, DCM Ventures and China’s H Capital.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
